[J&J]
Pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening blood vessel disorder, affects some 500 to 1,000 new patients each year in the U.S. FDA recently approved Opsynvi, a first-of-its-kind once-daily single-tablet combination therapy from Johnson & Johnson.“With this approval, our portfolio now includes treatments that address all three guideline-recommended pathways,” said a J&J spokesperson, highlighting the therapy’s alignment with current clinical guidelines recommending early use of combination therapy. The three treatment pathways include the endothelin, prostacyclin and nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathways.
The impact of Opsynvi PAH combination therapyBefore the approval, the DUE study for the combination therapy was featured in The Journal of the American College of Cardiology. The tria…